The swift growth of the regenerative medicine marketplace has created an immediate need for clinicians to distinguish between verified, responsibly sourced stem cell and exosome products and those that operate outside recognized quality standards.
While the preceding articles in this series concentrated on cell expansion standards and fundamental regulatory principles, this article evaluates a particular quality indicator that distinguishes reputable suppliers from others: Institutional Review Board (IRB) approval.
What is IRB Approval and Why Does It Matter?
An Institutional Review Board (IRB) is an autonomous committee officially appointed to review, approve, and oversee biomedical research involving human subjects [1]. The objective of IRB oversight is to ensure that suitable measures are implemented to safeguard the rights, welfare, and privacy of research participants [2]. In the context of stem cell and exosome products, IRB approval is significant for three reasons.
Firstly, the document affirms the importance of ethical oversight. IRB approval indicates that an independent third party has reviewed the proposed clinical protocol, including the informed consent process, risk-benefit analysis, and data safety monitoring plan [3]. This process helps ensure patient protection.
Secondly, it facilitates regulatory alignment. Although IRB approval does not constitute FDA approval, it establishes a systematic pathway for clinical investigation that complies with federal standards for human subjects’ research [4].
Third, it signifies the supplier’s credibility. A supplier that has obtained IRB approval for its products has dedicated time, resources, and documentation to fulfill stringent ethical and scientific standards. Many suppliers do not possess this credential at all [5].
Florida Stem Cell Law: IRB-Relevant Requirements
Florida Senate Bill 1768 (codified as Sections 458.3245 and 459.0127 of the Florida Statutes) came into effect on July 1, 2025. The legislation permits licensed physicians, including MDs and DOs, to administer stem cell therapies that are not FDA-approved, subject to specific conditions. The principal requirements are as follows:
- Limitation to specific clinical areas: Treatments must be for orthopedic conditions, wound care, or pain management [7].
- Ethical sourcing: The legislation explicitly prohibits the utilization of stem cells derived from aborted fetuses (constituting a third-degree felony) and instead promotes ethically sourced alternatives such as adult stem cells and umbilical cord blood [8].
- Informed consent: Patients must be provided with a clear written explanation indicating that the therapy is not approved by the FDA, including its potential benefits, risks, and available alternatives [9].
- Quality manufacturing standards: Stem cells must be “retrieved, manufactured, and stored in a facility registered and regulated by the United States Food and Drug Administration” and must comply with current Good Manufacturing Practices (cGMP) as outlined in 21 CFR Part 1271 [10].
- Accreditation: The facility must be accredited by a recognized entity, such as the American Association of Tissue Banks (AATB), the Association for the Advancement of Blood and Biotherapies (AABB), or the National Marrow Donor Program (NMDP) [11].
These requirements establish a comprehensive state-level framework for compliant, ethically sourced regenerative products that inherently integrate IRB-approved protocols.
RegenOMedix: IRB Approval for Exosome and Stem Cell Clinical Research
On February 6, 2026, RegenOMedix announced that it had obtained approval from the Institutional Review Board (IRB) for the clinical application of its Ascellos® stem cells and therapeutic exosomes in the fields of pain management, orthopedics, and wound healing [12]. The products designated for the study comply with the Florida Stem Cell Law [12].
Key elements of the RegenOMedix IRB approval include:
Protocol-Based Physician Participation
The Institutional Review Board (IRB) approval delineates established clinical protocols, ensuring that physicians contribute significantly to research endeavors while upholding ethical oversight and data collection standards [12].
Dedicated Patient Tracking
RegenOMedix utilizes a dedicated portal at ClinicalStudyResearch.com for patient tracking, facilitating structured data collection and outcome monitoring [12].
Clear Regulatory Boundaries
The IRB approval exclusively pertains to the oversight of the clinical study, adherence to protocol, and data collection activities. It does not imply FDA approval or authorization for marketing for therapeutic purposes, thereby clarifying the regulatory boundaries [12].
Targeted Clinical Areas of Interest
The Institutional Review Board (IRB)-approved study centers on joint and musculoskeletal pain, orthopedic injuries, and the management of chronic or complex wound healing, precisely within the scope authorized under Florida SB 1768 [12].
For clinicians, this IRB approval establishes a credible and compliant framework for participation in regenerative clinical research. Physicians are granted access to protocols, support, and resources for therapies such as stem cells, exosomes, PRP, shockwave therapy, and microneedling, all of which are conducted under structured oversight [13].
Why Documented Compliance Should Be Non-Negotiable
Licensed clinics should work only with suppliers that can document:
- IRB approval for the specific intended use of the product, where applicable.
- FDA establishment registration (tissue establishment registered with the FDA).
- cGMP compliance (21 CFR Part 1271) or appropriate regulatory framework.
- AATB accreditation or equivalent recognized accreditation.
- Lot-specific Certificates of Analysis documenting sterility, viability, and potency.
- Transparent sourcing documentation (ethical procurement, chain of custody).
Suppliers that cannot provide these documents should be evaluated with extreme caution.
Participating in IRB-Approved Research
Licensed physicians and medical clinics interested in participating in the RegenOMedix IRB-approved clinical program are encouraged to contact RegenOMedix directly. Participation provides a valuable opportunity to advance regenerative medicine and contribute to evidence-based care, while upholding the highest ethical and quality standards [12].
Disclaimer: This content is intended solely for educational and informational purposes. Presently, there are no FDA-approved exosome products for any therapeutic indication within the United States. These statements are derived from published guidelines and do not constitute legal advice or therapeutic claims. Healthcare practitioners should seek advice from qualified legal counsel and regulatory experts for guidance tailored to their specific practice.
References
[1] “Biosafety Manual – Stem Cell Research,” Stanford Environmental Health & Safety. [Online]. Available: https://ehs.stanford.edu/manual/biosafety-manual
[2] “Institutional Review Boards (IRBs) and Protection of Human Subjects in Clinical Trials,” FDA. [Online]. Available: https://www.fda.gov/about-fda/cder-offices-and-divisions/institutional-review-boards-irbs-and-protection-human-subjects-clinical-trials
[3] “The Challenges of First-in-Human Stem Cell Clinical Trials: What Does This Mean for Ethics and Institutional Review Boards?” PMC, 2018. [Online]. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC6028208/
[4] “IRB Approval for Stem Cell and Exosome Studies,” Temple Health. [Online]. Available: https://www.templehealth.org/services/stem-cell/exosome-therapy/irb-approval
[5] “FDA Cracking Down on Unapproved HCT/Ps with Fourth Untitled Letter of 2023,” National Law Review, 2023. [Online]. Available: https://www.natlawreview.com/article/fda-cracking-down-unapproved-hctps-fourth-untitled-letter-2023
[6] “CS/CS/SB 1768 (2025) – Enrollment,” Florida Senate, 2025. [Online]. Available: https://www.flsenate.gov/Session/Bill/2025/1768/BillText/er/HTML
[7] “Exosome Therapies – Karli Health,” Karli Health, Sep. 2025. [Online]. Available: https://www.karlihealth.com/exosome-therapies
[8] “Florida Stem Cell Law Flaunts the FDA,” Parents Guide to Cord Blood, Jun. 2025. [Online]. Available: https://parentsguidecordblood.org/en/news/florida-stem-cell-law-flaunts-fda
[9] “SB 1768 – 2025 Session Summary,” Florida Senate. [Online]. Available: https://www.flsenate.gov/Session/Bill/2025/1768
[10] “Current Good Tissue Practice (CGTP) and Additional Requirements for Manufacturers of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps),” FDA, May 2025. [Online]. Available: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-tissue-practice-cgtp-and-additional-requirements-manufacturers-human-cells-tissues-and
[11] “AATB Accreditation – American Association of Tissue Banks,” AATB. [Online]. Available: https://www.aatb.org/accreditation
[12] “RegenOMedix™ Receives IRB Approval for Clinical Use of Ascellos™ Stem Cells and Therapeutic Exosomes,” RegenOMedix, Feb. 2026. [Online]. Available: https://regenomedix.com/regenomedix-receives-irb-approval/
[13] “Stem Cell Conferences and Industry Events,” RegenOMedix, Jun. 2025. [Online]. Available: https://regenomedix.com/conferences/
